Relevant bibliographies by topics / Nelfinavir

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Nelfinavir'

Author: Grafiati
Published: 4 June 2021
Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nelfinavir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nelfinavir"

1

Bergshoeff, Alina S., Tom FW Wolfs, Sibyl PM Geelen, and David M. Burger. "Ritonavir-Enhanced Pharmacokinetics of Nelfinavir/M8 during Rifampin Use." Annals of Pharmacotherapy 37, no. 4 (April 2003): 521–25. http://dx.doi.org/10.1345/aph.1c335.

Full text
Abstract:
OBJECTIVE: To describe a case of successful protease inhibitor–based highly active antiretroviral therapy (HAART) concomitant with rifampin. CASE SUMMARY: In a 7-month-old male infant with tuberculosis and HIV-1 infection, tuberculosis therapy including rifampin and HAART containing the protease inhibitor nelfinavir 40 mg/kg every 8 hours was started. Intensive steady-state pharmacokinetic sampling from baseline to 8 hours revealed very low plasma concentrations of nelfinavir: area under the plasma concentration–time curve (AUC0–24) <10% of adult population values for 750 mg every 8 hours and nonquantifiable concentrations of nelfinavir's principal metabolite (M8). Nelfinavir 40 mg/kg every 8 hours was then substituted with nelfinavir 30 mg/kg twice daily plus ritonavir 400 mg/m2 twice daily. Intensive steady-state (0–12 h) pharmacokinetic sampling was repeated. Nelfinavir concentrations had improved, but remained low when compared with adult population values of 1250 mg every 12 hours: AUC0–24 21.9 versus 47.6 mg/L•h (46%) and 12-hour trough level (C12) 0.25 versus 0.85 mg/L (29%). However, concentrations of M8 considerably exceeded population values: AUC0–24 57.5 versus 13.6 mg/L•h (443%) and C12 1.35 versus 0.28 mg/L (482%). Since M8 concentrations were highly elevated, pharmacokinetic parameters for (nelfinavir + M8) were used rather than those for nelfinavir alone. Thus, AUC0–24 (nelfinavir + M8) and C12 (nelfinavir + M8) comprised 130% and 142%, respectively of the adult population values. This, in addition to good clinical response and tolerability, favored continuation of the regimen. CONCLUSIONS: In an infant, nelfinavir-containing HAART was successfully used with rifampin after the addition of ritonavir. Ritonavir resolved the pharmacokinetic interaction between rifampin and nelfinavir by boosting nelfinavir and, especially, M8 concentrations. More research is needed to confirm these results.
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Nelfinavir." Reactions Weekly &NA;, no. 1200 (May 2008): 25. http://dx.doi.org/10.2165/00128415-200812000-00070.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jarvis, Blair, and Diana Faulds. "Nelfinavir." Drugs 56, no. 1 (1998): 147–67. http://dx.doi.org/10.2165/00003495-199856010-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bardsley-Elliot, Anne, and Greg L. Plosker. "Nelfinavir." Drugs 59, no. 3 (March 2000): 581–620. http://dx.doi.org/10.2165/00003495-200059030-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Perry, Caroline M., James E. Frampton, Paul L. McCormack, M. Asif A. Siddiqui, and Risto S. Cvetkovi?? "Nelfinavir." Drugs 65, no. 15 (2005): 2209–44. http://dx.doi.org/10.2165/00003495-200565150-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Nelfinavir." Reactions Weekly &NA;, no. 788 (February 2000): 9. http://dx.doi.org/10.2165/00128415-200007880-00028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Nelfinavir." Reactions Weekly &NA;, no. 804 (June 2000): 10. http://dx.doi.org/10.2165/00128415-200008040-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Nelfinavir." Reactions Weekly &NA;, no. 814 (August 2000): 10. http://dx.doi.org/10.2165/00128415-200008140-00027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Nelfinavir." Drugs & Therapy Perspectives 10, no. 12 (December 1997): 7–9. http://dx.doi.org/10.2165/00042310-199710120-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Nelfinavir." Reactions Weekly &NA;, no. 733 (January 1999): 10–11. http://dx.doi.org/10.2165/00128415-199907330-00026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Nelfinavir"

1

Hirt, Déborah. "Pharmacocinétique de population du nelfinavir." Paris 5, 2006. http://www.theses.fr/2006PA05P636.

Full text
Abstract:
Le nelfinavir est un inhibiteur de protéase utilisé dans le traitement du SIDA. Ce médicament est métabolisé par le CYP2C19 en un métabolite actif, le M8. Il existe une grande variabilité interindividuelle des concentrations plasmatiques de nelfinavir et de M8 avec des conséquences pour l’efficacité thérapeutique. Dans quatre publications différentes, nous avons analysé les facteurs de variabilité de ces concentrations grâce à une méthode de pharmacocinétique de population : chez la femme enceinte et au cours de l’accouchement, chez l’enfant et le fœtus et chez les sujets présentant un polymorphisme génétique pour le CYP2C19. Puis à partir des estimations des paramètres pharmacocinétiques individuelles, nous avons calculé la dose nécessaire pour atteindre une concentration efficace. Lorsque nous disposions de mesures d’efficacité et de toxicité, des relations pharmacocinétique – pharmacodynamique ont été étudiées. Ces résultats ont permis des recommandations posologiques adaptées
Nelfinavir is a protease inhibitor used for AIDS treatment. This drug is metabolized by CYP2C19 to an active metabolite, M8. There is a high interindividual variability in nelfinavir and M8 plasma concentrations, with consequences on therapeutic efficacy. In four different publications, we analyzed variability factors of these concentrations thanks to population pharmacokinetics method: in pregnant women and women at delivery, in children and fetus and in adults with genetic polymorphism for the CYP2C19. Then, from the estimated individual pharmacokinetic parameters, we calculated minimal dose necessary to reach an effective concentration. When data concerning efficacy and toxicity were available, pharmacokinetic – pharmacodynamic relationships were studied. The results obtained permitted to give adapted doses recommendations
APA, Harvard, Vancouver, ISO, and other styles
2

Hones, Stefanie. "Identifizierung und Regulation Nelfinavir-induzierter Peptidhormone." Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-160475.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Portolan, Frédérique. "Recherche sur les antiviraux anti-VIH : synthèse des immunogènes de l'indinavir et du nelfinavir, mise au point des dosages radio-immunologiques de ces anti-protéases." Nice, 2001. http://www.theses.fr/2001NICE5624.

Full text
Abstract:
Ce travail vise à développer des dosages radio-immunologiques de l’IDV et du NFV, deux anti-protéases utilisées en chimiothérapie anti-VIH. Pour cela, nous avons préparé les haptènes et les immunogènes de l’IDV et du NFV en vue d’obtenir les anticorps nécessaires au développement du dosage. Aussi , nous avons développé le premier dosage RIA de l’Indinavir. L’immunisation de lapins par le conjugué IDV-4(S)-HS-KLH et l’utilisation du traceur IDV-4(S)-HS-GT-I* pour la caractérisation des anticorps nous ont permis de sélectionner un immunosérum présentant un titre élevé (1/4. 10 puissance 4) et une affinité importante (IC indice 50 de 1,3. 10 puissance -9 M). Ce dernier possède une spécificité intéressante puisqu’aucune autre anti-PR n’est reconnue par les anticorps anti-IDV. Cette caractéristique nous permettra de doser des échantillons provenant de patients traités par l’IDV. Nous avons appliqué ce dosage à un modèle in vitro mimant les conditions physiologiques permettant d’évaluer les taux intracellulaires de l’IDV. Les premiers résultats montrent des quantités voisines de 2 nmoles. Uns stratégie similaire a été appliquée au NFV. L’immunisation a été réalisée à l’aide de l’immunogène NVF-AcO-BSA. Les premiers anticoprs anti-NFV obtenus ont été caractérisés à l’aide d’un traceur NFV-I*. Dans ces conditions, l’immunosérum sélectionné possède un titre de 1/3000ème et une affinité de 10 puissance -7 M. Cependant, ce dosage nous a semblé trop peu sensible pour la détermination des taux intracellulaires de cette anti-PR. Nous avons alors préféré développer un autre dosage du NFV en changeant la structure chimique de l’immunogène : NFV-AcO-βAla-KLH. La caractérisation des anticorps, à l’aide du traceur NFV-AcO-βAla-GT-I* a permis de sélectionner un immunosérum présentant un titre de 1/1,5. 10 puissance 6. L’affinité des anticorps (4. 10 puissance -9 M) est suffisante pour doser les quantités intracellulaires de NFV. De plus, ce dosage est spécifique puisque les anticorps ne reconnaissent pas les anti-PR utilisées dans le traitement du SIDA.
APA, Harvard, Vancouver, ISO, and other styles
4

Hones, Stefanie [Verfasser], and Ioannis [Akademischer Betreuer] Mylonas. "Identifizierung und Regulation Nelfinavir-induzierter Peptidhormone / Stefanie Hones. Betreuer: Ioannis Mylonas." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2013. http://d-nb.info/1042147329/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cristina, da Silva Monteiro Vandessa. "Tecnologia de obtenção de anti-retroviral à base de Mesilato de Nelfinavir." Universidade Federal de Pernambuco, 2005. https://repositorio.ufpe.br/handle/123456789/3507.

Full text
Abstract:
Made available in DSpace on 2014-06-12T16:31:34Z (GMT). No. of bitstreams: 2 arquivo6106_1.pdf: 2159514 bytes, checksum: 67a8083fdccc3096c53639c1f47b0ac1 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2005
Os Inibidores de protease (PI) constituem uma potente classe de drogas anti-retrovirais que mudou o tratamento e a evolução da infecção pelo HIV. Em março de 1997, um novo medicamento desta classe, o mesilato de nelfinavir foi aprovado pela Food and Drug Administration (FDA), sendo desde então, extensamente utilizado isoladamente ou em associação a Inibidores da Transcriptase Reversa (RTIs), obtendo-se considerável eficácia clínica no tratamento da AIDS. O mesilato de nelfinavir tem como produto de referência no mercado o Viracept®, fabricado pela indústria Roche. Esta medicação faz parte do coquetel anti-AIDS distribuído no Brasil, sendo usada por 25% dos pacientes. O presente trabalho tem como objetivo apresentar o desenvolvimento farmacotécnico-industrial de comprimidos revestidos de mesilato de nelfinavir 250 mg, baseado em uma planificação qualitativa e quantitativa dos excipientes, além da realização de testes de bancada visando à obtenção de uma forma farmacêutica com qualidade e baixo custo. Para tanto, realizou-se a caracterização da matéria-prima com vistas à qualificação de fornecedores, e executou-se o desenvolvimento da metodologia de dissolução para os comprimidos obtidos, além de estudo comparativo do seu perfil de dissolução frente ao medicamento de referência. O trabalho também contemplou o desenvolvimento e a validação da metodologia para doseamento da matéria-prima e produto acabado, por Cromatografia Líquida de Alta Eficiência (CLAE), obedecendo aos parâmetros estabelecidos na Resolução-RE n° 899, publicada em 02 de junho de 2003 pela Agência Nacional de Vigilância Sanitária (ANVISA). Também foi realizado um estudo comparativo entre o produto de referência Viracept® e o produto desenvolvido mesilato de nelfinavir LAFEPE®. Os comprimidos revestidos de mesilato de nelfinavir desenvolvidos apresentaram boa qualidade e as comparações efetuadas entre estes e o Viracept® não apresentaram diferenças significativas. Encontra-se em curso o estudo de estabilidade nos modelos acelerado e longa duração. Este estudo foi realizado em parceria com o Núcleo de Controle de Qualidade de Medicamentos e Correlatos, o Laboratório de Tecnologia dos Medicamentos, ambos do Departamento de Ciências Farmacêuticas da UFPE e o Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE)
APA, Harvard, Vancouver, ISO, and other styles
6

Chaworth-Musters, Tessa. "Plasma concentrations of nelfinavir and viral suppression in HIV-1 infected pregnant women." Thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/965.

Full text
Abstract:
BACKGROUND: Highly active antiretroviral therapy(HAART) is used in pregnancy to suppress viral load(pVL) before delivery, reducing risk of vertical HIV-transmission. Nelfinavir(NFV) containing HAART has been highly used in pregnancy, but dosages may be inadequate due to the physiologic changes that occur. Given concerns regarding optimal viral suppression in pregnancy, drug toxicity and resistance development, NFV levels need to be evaluated in this population to guide dosing recommendations. METHODS: As part of a prospective cohort study maternal blood was collected at 18-28wks, 32-37wks and at delivery. Times of last medication dose and blood sampling were recorded and drug levels were measured using HPLC MS-MS. NFV concentration-ratios(NFV-CRs) were calculated by dividing individual levels by a time-adjusted population value. Plasma NFV concentrations and NFV-CRs were compared across gestational age and correlated to variables of interest. Rate and maintenance of viral suppression were analyzed in relation to NFV concentrations and CRs. Statistical tests included ANOVA, χ2, linear regression, and Kaplan Meier estimates. RESULTS: 113 samples were collected from 32 subjects. Samples were eliminated if not in steady state (n=20); 93 samples from 32 subjects were analyzed. Mean NFV-CR at 18-28wks (1.1±0.73) and 32-37wks (0.86±0.73) were not significantly different but were both significantly higher by ANOVA (p=0.049) than the mean NFV-CR at delivery (0.44±0.50). CRs were highly variable. Of 49 antepartum samples, 49%(24) had a CR<0.90 (clinically relevant threshold). Four women reached a pVL <50 copies/mL by 34wks but had a detectable pVL at delivery. One woman never reached an undetectable pVL in pregnancy. Minimum and mean NFV-CRs in these 5 women were not significantly different than those who achieved and maintained virologic suppression. Vertical HIV transmission rate was 0%. CONCLUSIONS: There were no HIV transmissions but 16% (5/32) of women were inadequately suppressed at delivery, which is of concern. Factors associated with inadequate suppression and NFV-CRs need to be explored in conjunction with patient/physician reported adherence and viral resistance profiles. Extreme variability in CRs may limit the potential usefulness of random timed drug levels in all pregnant women.
APA, Harvard, Vancouver, ISO, and other styles
7

Batista, Rui. "Pharmacocinétique du nelfinavir chez des patients atteints de complications neurologiques dues au VIH-1." Paris 5, 1999. http://www.theses.fr/1999PA05P159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

HOLANDA, Luiz Henrique Campos. "Análise conformacional da enzima protease do HIV-1 relacionada à resistência ao inibidor Nelfinavir." Universidade Federal do Pará, 2017. http://repositorio.ufpa.br/jspui/handle/2011/9249.

Full text
Abstract:
Submitted by Cássio da Cruz Nogueira (cassionogueirakk@gmail.com) on 2017-10-18T15:37:16Z No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseConformacionalEnzima.pdf: 2962750 bytes, checksum: a3dc63037d6a89e63bf949b46941a41e (MD5)
Approved for entry into archive by Irvana Coutinho (irvana@ufpa.br) on 2017-11-14T14:05:55Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseConformacionalEnzima.pdf: 2962750 bytes, checksum: a3dc63037d6a89e63bf949b46941a41e (MD5)
Made available in DSpace on 2017-11-14T14:05:55Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Dissertacao_AnaliseConformacionalEnzima.pdf: 2962750 bytes, checksum: a3dc63037d6a89e63bf949b46941a41e (MD5) Previous issue date: 2017
CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
O Vírus da imunodeficiência humana (HIV), causador da síndrome da imunodeficiência adquirida (AIDS), é um retrovírus que possui glicoproteínas altamente virulentas que invadem o linfócito TCD4+ através de seus receptores CCR4 e CXCR5. O ciclo biológico do HIV é mediado pelas enzimas protease, transcriptase e integrase. A HIV-1 protease é uma enzima que está presente na fase final do ciclo biológico, onde ocorre a maturação do vírus e é um importante alvo farmacológico. O objetivo principal deste projeto é verificar os efeitos das mutações D30N, I84A e M46I na enzima protease HIV-1 e na formação do complexo com o inibidor nelfinavir através de técnicas de dinâmica molecular e bioinformática. Os resultados baseados nas análises estruturais mostraram diferenças estruturais entre os sistemas estudados. O sistema 1OHR apresentou uma conformação fechada, os sistemas D30N e D30N_I84A_M46I apresentaram conformação semi-aberta e o sistema D30N_I84A apresentou conformação aberta, em que o último apresentou menor valor de energia livre e maior instabilidade nas análises de RMSD, porém a maior flutuação de resíduos de aminoácidos. As análises teóricas mostraram a importância na resistência da dupla mutação D30N_I84A e a capacidade de reestruturação conformacional da mutação M46I e capacidade catalítica.
The Human Immunodeficiency Virus (HIV), which causes acquired immunodeficiency syndrome (AIDS), is a retrovirus that has highly virulent glycoproteins that invade the CD4 + T lymphocyte through its CCR4 and CXCR5 receptors. The biological cycle of HIV is mediated by the protease, transcriptase and integrase enzymes. HIV-1 protease is an enzyme that is present in the final phase of the biological cycle, where virus maturation occurs, and is an important pharmacological target. The main objective of this project is to verify the effects of the D30N, I84A and M46I mutations on the HIV-1 protease enzyme and the complex formation with the nelfinavir inhibitor through molecular dynamics and bioinformatics techniques. The results based on the structural analyzes showed structural differences between the studied systems. The 1OHR system presented a closed conformation, the systems D30N and D30N_I84A_M46I presented semi-open conformation and the D30N_I84A system presented open conformation, in which the latter presented lower free energy value and greater instability in the RMSD analyzes, however the greater flotation of residues Of amino acids. The theoretical analyzes showed the importance in the resistance of the double mutation D30N_I84A and the conformational restructuring capacity of the M46I mutation and catalytic capacity.
APA, Harvard, Vancouver, ISO, and other styles
9

Lenzner, Luzie [Verfasser]. "Apoptoseinduktion in kolorektalen Zellen und Gewebe durch die HIV-Proteaseinhibitoren Saquinavir und Nelfinavir / Luzie Lenzner." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2013. http://d-nb.info/1032558938/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Payen, Salomé. "Intérêt de la pharmacocinétique de population pour l'adaptation posologique et le suivi thérapeutique en pédiatrie." Montpellier 1, 2004. http://www.theses.fr/2004MON13502.

Full text
Abstract:
Les études pharmacocinétiques en pédiatrie sont importantes en raison des transformations liées à la maturation dont il faudra tenir compte dans la prescription des médicaments. Dans la première partie de notre thèse nous exposerons les données bibliographiques concernant les modifications des paramètres pharmacocinétiques chez l'enfant ainsi que l'intérêt de l'utilisation de la pharmacocinétique de population en pédiatrie. Nous présenterons ensuite notre travail personnel concernant la pharmacocinétique de population de la ciprofloxacine, du nelfinavir et du mycophénolate mofétil. Le logiciel NONMEM a été utilisé pour ces analyses. Après un bref rappel sur la pharmacologie des fluoroquinolones, les relations structure activité et structure toxicité, nous présenterons les résultats d'une étude pharmacocinétique réalisée chez 55 patients âgés de 1 jour à 24 ans. Le modèle structurel prend en compte une relation entre clairance totale de la ciprofloxacine et âge et état clinique du patient (fibrose cystique ou non). Une stratégie de prélèvement limité est proposée. Ce travail constitue la deuxième partie de notre thèse. Dans une troisième partie, après un rappel sur la pharmacologie des antirétroviraux, nous présenterons l'étude pharmacocinétique du nelfinavir et de son métabolite actif (M8) chez des enfants âgés de moins de 3 mois. Les paramètres pharmacocinétiques individuels ont été estimés par approche Bayésienne empirique. Le modèle structurel permet l'analyse simultanée des données plasmatiques du nelfinavir et du M8. L'influence de l'âge et du poids sur les paramètres pharmacocinétiques estimés a été évaluée. Enfin, la dernière partie de notre travail concerne la détermination des paramètres pharmacocinétiques du mycophénolate mofétil chez des enfants et adolescents transplantés rénaux. Une stratégie avec deux prélèvements permet l'estimation de l'aire sous la courbe des concentrations plasmatiques d'acide mycophénolique sans biais et avec une bonne précision
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Nelfinavir"

1

Blokdijk, G. J. Nelfinavir Mesylate; A Complete Guide. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Patel, Manish. A pilot study of therapeutic drug monitoring of nelfinavir in HIV infected patients. 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Raymond, Colette. Response to nelfinavir in patients previously exposed to protease inhibitors--an Expanded Access Program in Ottawa, Ontario. 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Nelfinavir"

1

Raposo, L. M., M. B. Arruda, R. M. Brindeiro, and F. F. Nobre. "Logistic Regression Models for Predicting Resistance to HIV Protease Inhibitor Nelfinavir." In IFMBE Proceedings, 1237–40. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-00846-2_306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hengge, U. R., V. Exner, S. Esser, H. P. Rudel, K. Müller, and M. Goos. "Effektivität, Verträglichkeit und Sicherheit einer Kombinationstherapie mit Stavudin, Didanosin und Nelfinavir in naiven vs. vorbehandelten HIV-Patienten: 18 Monatsdaten." In HIV-Infekt, 235–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hoffmann, F., G. Notheis, U. Wintergerst, J. Eberle, L. Gürtler, and B. H. Belohradsky. "Antiretrovirale Salvage-Therapie mit zwei Proteaseinhibitoren bei HIV-infizierten Kindern: Vergleich von Kombinations-therapien mit Ritonavir/Saquinavir und Nelfinavir/Saquinavir." In HIV-Infekt, 301–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59683-4_53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Nelfinavir." In Meyler's Side Effects of Drugs, 44–47. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01135-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Findlay, Victoria J. "Nelfinavir." In xPharm: The Comprehensive Pharmacology Reference, 1–6. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62257-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"NELFINAVIR." In Litt's Drug Eruptions and Reactions Manual, 304. CRC Press, 2014. http://dx.doi.org/10.1201/b15347-142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Nelfinavir." In PharmacotherapyFirst Drug Information. 2215 Constitution Avenue, N.W. Washington, DC 20037-2985: The American Pharmacists Association, 2017. http://dx.doi.org/10.21019/druginformation.nelfinavir.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Nelfinavir." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2433–35. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00770-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jensen-Fangei, Soren, Suzanne Crowe, and Lars Ostergaard. "Nelfinavir." In Kucers' The Use of Antibiotics Sixth Edition, 2788–96. CRC Press, 2010. http://dx.doi.org/10.1201/b13787-274.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Nelfinavir (NFV)." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Stuttgart: Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82615.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Nelfinavir"

1

Methaneethorn, Janthima, Patcharaporn Kunyamee, Warangkana Jindasri, Warunee Wattanasaovaluk, Anoot Kraiboot, and Manupat Lohitnavy. "Pharmacokinetic modeling of simvastatin, nelfinavir and their interaction in humans." In 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2014. http://dx.doi.org/10.1109/embc.2014.6944925.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Probabilistic Neural Network for Predicting Resistance to HIV-Protease Inhibitor Nelfinavir." In International Conference on Bioinformatics Models, Methods and Algorithms. SCITEPRESS - Science and and Technology Publications, 2014. http://dx.doi.org/10.5220/0004735900170023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kushchayeva, Yevgeniya, Aneeta Patel, John Costello, Vasyl Vasko, Nancy Carroll, Rubie Sue Jackson, Kenneth Burman, and Lisa Boyle. "Abstract 2124: The HIV protease inhibitor Nelfinavir inhibits medullary thyroid cancer cell growth." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kalu, Nene, Sunetra Biswas, Courtney Shirley, Meir Shamay, and Richard F. Ambinder. "Abstract C19: Nelfinavir-induced autophagy and cell death as potential anticancer therapy for KSHV-associated lymphomas." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sanchez, Cecilia G., Fuselier Taylor, Marguerite Changala, Fayong Luo, and Joseph A. Lasky. "Nelfinavir Inhibits Myofibroblasts Differentiation And Induces Autophagic Degradation Of Type I Collagen In Human Lung Myofibroblasts." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3505.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Subeha, Mahbuba R., Alicia A. Goyeneche, and Carlos M. Telleria. "Abstract 1013: Mechanistic role of nelfinavir as drug-repurposing strategy against high-grade serous ovarian cancer." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kawabata, Shigeru, Nick Connis, Chunyu Zhang, Joell J. Gills, Christine L. Hann, and Phillip A. Dennis. "Abstract 684: Nelfinavir inhibits the growth of small cell lung cancer cells and patient-derived xenograft tumors." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-684.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mathur, Aditi, Mikhail L. Kostochka, Asim B. Abdel-Mageed, and Debasis Mondal. "Abstract B42: Nelfinavir potentiates the anti-cancer efficacy of curcumin by subverting endoplasmic reticulum stress toward apoptosis: A promising chemoprevention approach." In Abstracts: Thirteenth Annual AACR International Conference on Frontiers in Cancer Prevention Research; September 27 - October 1, 2014; New Orleans, LA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1940-6215.prev-14-b42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chang, Yoon Soo, Leah M. Meza, Masahiro Onozawa, Joell J. Gills, Peter D. Aplan, and Phillip A. Dennis. "Abstract 2603: Inhibition of Notch and mTOR by nelfinavir as a novel approach for T cell acute lymphoblastic leukemia (T-ALL)." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2603.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Guan, Min. "Abstract 2653: Nelfinavir induces apoptosis in hormone-resistant prostate cancer cells through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Nelfinavir' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography